Coya Therapeutics Receives $4.2M Milestone Payment

Coya Therapeutics, Inc. ( (COYA) ) has shared an announcement.

On December 16, 2025, Coya Therapeutics, Inc. received a $4.2 million milestone payment under a Development and License Agreement with Dr. Reddy’s Laboratories. This payment was triggered by the dosing of the first patient in the company’s ALSTARS trial, which aims to evaluate COYA 302 for treating ALS. The milestone highlights progress in their ALS treatment efforts and reflects positively on the collaboration between Coya and Dr. Reddy’s Laboratories, marking a significant step forward in advancing its clinical operations.

The most recent analyst rating on (COYA) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.

Spark’s Take on COYA Stock

According to Spark, TipRanks’ AI Analyst, COYA is a Neutral.

Coya Therapeutics, Inc. has a mixed outlook. Strong clinical progress and financial stability from a debt-free balance sheet with cash reserves are significant positives. However, persistent profitability and cash flow challenges weigh heavily on the overall score. Technical indicators suggest moderate momentum, while valuation remains pressured by ongoing losses. The company’s strategic advancements and funding efforts are positive but need to translate into improved financial performance to enhance the stock’s appeal.

To see Spark’s full report on COYA stock, click here.

More about Coya Therapeutics, Inc.

Coya Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of innovative therapeutics for neurodegenerative and autoimmune diseases including treatments for amyotrophic lateral sclerosis (ALS).

Average Trading Volume: 197,692

Technical Sentiment Signal: Sell

Current Market Cap: $122M

Find detailed analytics on COYA stock on TipRanks’ Stock Analysis page.